FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200316162> ?p ?o ?g. }

• W4200316162 abstract "Objective: The CAMEL clinical trial (412 patients were randomly assigned to either camrelizumab plus chemotherapy (n = 205) or chemotherapy alone (n = 207)) demonstrated that camrelizumab plus chemotherapy (CC) improved the overall survival time (OS) and progression-free survival time (PFS) of patients with metastatic nonsquamous non-small cell lung cancer (non-sq NSCLC) without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations (EGFRm and ALKm) vs. chemotherapy (C) alone. Our objective was to conduct a cost-effectiveness analysis of CC vs. C from a perspective of health - care system in China with a lifetime horizon to identify whether it will be cost-effective. Materials and Methods: A partitioned survival model (PSM) was applied for patients with IIIB-IV non-sq NSCLC without EGFRm and ALKm. Transition parameters and proportions of three health states were derived from the CAMEL trial. The model was designed using a lifetime horizon, a 21-day cycle, and a 5% discount rate of costs and outcomes. It was deemed cost-effective in China if the incremental cost-effectiveness ratio (ICER) value is less than $32,457 per quality adjusted life-year (QALY). Deterministic and probabilistic sensitivity analyses were performed to verify the influence of parameter uncertainty on the results. Results: In the base-case analysis, we found that the ICER of CC compared with C is $-7,382.72/QALY which meant that CC had lower costs and better outcomes. The results of the sensitivity analyses demonstrated that the result was robust for the ICERs never transcending the willingness-to-pay (WTP) threshold. Conclusion: Camrelizumab plus chemotherapy is an obviously cost-effective therapeutic regime for patients of IIIB-IV non-sq NSCLC without EGFRm and ALKm in China at a $32,457 WTP threshold." @default.
• W4200316162 created "2021-12-31" @default.
• W4200316162 creator A5002982580 @default.
• W4200316162 creator A5017090255 @default.
• W4200316162 creator A5030981835 @default.
• W4200316162 creator A5042708897 @default.
• W4200316162 creator A5068730328 @default.
• W4200316162 creator A5070602177 @default.
• W4200316162 creator A5083407152 @default.
• W4200316162 date "2021-12-24" @default.
• W4200316162 modified "2023-10-14" @default.
• W4200316162 title "Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB–IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China" @default.
• W4200316162 cites W1975731597 @default.
• W4200316162 cites W1977373411 @default.
• W4200316162 cites W1982967337 @default.
• W4200316162 cites W2011746683 @default.
• W4200316162 cites W2123091553 @default.
• W4200316162 cites W2128473443 @default.
• W4200316162 cites W2135140316 @default.
• W4200316162 cites W2145835533 @default.
• W4200316162 cites W2296800272 @default.
• W4200316162 cites W2519603001 @default.
• W4200316162 cites W2567353654 @default.
• W4200316162 cites W2744137087 @default.
• W4200316162 cites W2753207486 @default.
• W4200316162 cites W2769988386 @default.
• W4200316162 cites W2796582438 @default.
• W4200316162 cites W2805354595 @default.
• W4200316162 cites W2946386783 @default.
• W4200316162 cites W2951071083 @default.
• W4200316162 cites W2991564522 @default.
• W4200316162 cites W3000746124 @default.
• W4200316162 cites W3046449570 @default.
• W4200316162 cites W3081464123 @default.
• W4200316162 cites W3111665711 @default.
• W4200316162 cites W3125795216 @default.
• W4200316162 cites W3134028252 @default.
• W4200316162 cites W3208194388 @default.
• W4200316162 cites W4205565459 @default.
• W4200316162 cites W4210992155 @default.
• W4200316162 doi "https://doi.org/10.3389/fphar.2021.735536" @default.
• W4200316162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35002693" @default.
• W4200316162 hasPublicationYear "2021" @default.
• W4200316162 type Work @default.
• W4200316162 citedByCount "16" @default.
• W4200316162 countsByYear W42003161622022 @default.
• W4200316162 countsByYear W42003161622023 @default.
• W4200316162 crossrefType "journal-article" @default.
• W4200316162 hasAuthorship W4200316162A5002982580 @default.
• W4200316162 hasAuthorship W4200316162A5017090255 @default.
• W4200316162 hasAuthorship W4200316162A5030981835 @default.
• W4200316162 hasAuthorship W4200316162A5042708897 @default.
• W4200316162 hasAuthorship W4200316162A5068730328 @default.
• W4200316162 hasAuthorship W4200316162A5070602177 @default.
• W4200316162 hasAuthorship W4200316162A5083407152 @default.
• W4200316162 hasBestOaLocation W42003161621 @default.
• W4200316162 hasConcept C112930515 @default.
• W4200316162 hasConcept C117643217 @default.
• W4200316162 hasConcept C121608353 @default.
• W4200316162 hasConcept C126322002 @default.
• W4200316162 hasConcept C143998085 @default.
• W4200316162 hasConcept C2776232967 @default.
• W4200316162 hasConcept C2776256026 @default.
• W4200316162 hasConcept C2776694085 @default.
• W4200316162 hasConcept C2777240266 @default.
• W4200316162 hasConcept C2778239845 @default.
• W4200316162 hasConcept C2779438470 @default.
• W4200316162 hasConcept C3019080777 @default.
• W4200316162 hasConcept C515549039 @default.
• W4200316162 hasConcept C71924100 @default.
• W4200316162 hasConceptScore W4200316162C112930515 @default.
• W4200316162 hasConceptScore W4200316162C117643217 @default.
• W4200316162 hasConceptScore W4200316162C121608353 @default.
• W4200316162 hasConceptScore W4200316162C126322002 @default.
• W4200316162 hasConceptScore W4200316162C143998085 @default.
• W4200316162 hasConceptScore W4200316162C2776232967 @default.
• W4200316162 hasConceptScore W4200316162C2776256026 @default.
• W4200316162 hasConceptScore W4200316162C2776694085 @default.
• W4200316162 hasConceptScore W4200316162C2777240266 @default.
• W4200316162 hasConceptScore W4200316162C2778239845 @default.
• W4200316162 hasConceptScore W4200316162C2779438470 @default.
• W4200316162 hasConceptScore W4200316162C3019080777 @default.
• W4200316162 hasConceptScore W4200316162C515549039 @default.
• W4200316162 hasConceptScore W4200316162C71924100 @default.
• W4200316162 hasLocation W42003161621 @default.
• W4200316162 hasLocation W42003161622 @default.
• W4200316162 hasLocation W42003161623 @default.
• W4200316162 hasLocation W42003161624 @default.
• W4200316162 hasOpenAccess W4200316162 @default.
• W4200316162 hasPrimaryLocation W42003161621 @default.
• W4200316162 hasRelatedWork W1591408781 @default.
• W4200316162 hasRelatedWork W1600335608 @default.
• W4200316162 hasRelatedWork W2374494252 @default.
• W4200316162 hasRelatedWork W2768988395 @default.
• W4200316162 hasRelatedWork W2894792775 @default.
• W4200316162 hasRelatedWork W2998686349 @default.
• W4200316162 hasRelatedWork W3011176692 @default.
• W4200316162 hasRelatedWork W3029430426 @default.
• W4200316162 hasRelatedWork W4200316162 @default.
• W4200316162 hasRelatedWork W4254666574 @default.

• next